Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFM) Shares Outstanding (Weighted Average): 2020-2025

Historic Shares Outstanding (Weighted Average) for Sunshine Biopharma (SBFM) over the last 6 years, with Sep 2025 value amounting to $4.6 million.

  • Sunshine Biopharma's Shares Outstanding (Weighted Average) rose 272.11% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year increase of 272.11%. This contributed to the annual value of $2.0 million for FY2024, which is 15474.89% up from last year.
  • According to the latest figures from Q3 2025, Sunshine Biopharma's Shares Outstanding (Weighted Average) is $4.6 million, which was down 0.00% from $4.6 million recorded in Q2 2025.
  • Sunshine Biopharma's 5-year Shares Outstanding (Weighted Average) high stood at $4.6 million for Q2 2025, and its period low was $1,163 during Q1 2021.
  • In the last 3 years, Sunshine Biopharma's Shares Outstanding (Weighted Average) had a median value of $947,253 in 2024 and averaged $1.4 million.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first decreased by 10.75% in 2021, then surged by 15,474.89% in 2024.
  • MRQ analysis of 5 years shows Sunshine Biopharma's Shares Outstanding (Weighted Average) stood at $1,288 in 2021, then surged by 776.79% to $11,293 in 2022, then increased by 13.69% to $12,839 in 2023, then skyrocketed by 15,474.89% to $2.0 million in 2024, then skyrocketed by 127.84% to $4.6 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $4.6 million for Q3 2025, versus $4.6 million for Q2 2025 and $2.0 million for Q1 2025.